New eczema drug enters first human tests
NCT ID NCT07604324
First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called DCY636 for safety and tolerability in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The trial has two parts: a single dose in healthy adults and multiple doses in eczema patients. It aims to gather initial safety data to support further development.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DCY636
- What this could lead to
- If this early trial shows DCY636 is safe, it could pave the way for a new treatment option for people with moderate to severe atopic dermatitis.
- What could go wrong
- This is a very early Phase 1 study focused on safety, not effectiveness. The drug may not work or could have side effects. It will take years before any potential treatment is available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGFukuoka, 812-0025, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World dupixent: does it live up to the hype for eczema?
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates
- Eczema drug nemolizumab put to the vaccine test
- Eczema drug study pulled before it started
- New eczema drug shows promise in Mid-Stage trial